IMMU-36. HIGH AFFINITY CHIMERIC ANTIGEN RECEPTOR WITH CROSS-REACTIVITY TO CLINICALLY-RELEVANT EGFR MUTATED PROTEINS

Tumor heterogeneity is one of the key reasons for therapeutic failure in Glioblastoma (GBM). Our chimeric antigen receptor (CAR) T cell clinical trial (NCT02209376) against Epidermal growth factor receptor (EGFR) variant III (EGFRvIII) demonstrated successful trafficking of T cells across the blood...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Thokala, Radhika, Binder, Zev, Yin, Yibo, Milone, Michael, O’Rourke, Donald M
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Immunology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650978/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.466
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg